

Steven Larson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5320743/publications.pdf>

Version: 2024-02-01

232
papers

19,982
citations

7096

78
h-index

11939

134
g-index

242
all docs

242
docs citations

242
times ranked

17939
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 7053-7058.	7.0	608
2	Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. <i>Science Translational Medicine</i> , 2014, 6, 260ra149.	12.4	589
3	Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. <i>Journal of Clinical Investigation</i> , 2011, 121, 2768-2780.	8.2	558
4	Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging The Visual Response Score and the Change in Total Lesion Glycolysis. <i>Molecular Imaging and Biology</i> , 1999, 2, 159-171.	0.3	516
5	Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 498-505.	3.6	513
6	Intensity of ¹⁸ F-fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 4643-4651.	1.6	462
7	Fluorescent Silica Nanoparticles with Efficient Urinary Excretion for Nanomedicine. <i>Nano Letters</i> , 2009, 9, 442-448.	9.1	441
8	Radioimmunotherapy of human tumours. <i>Nature Reviews Cancer</i> , 2015, 15, 347-360.	28.4	382
9	Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. <i>Cancer</i> , 1997, 80, 2505-2509.	4.1	377
10	⁸⁹ Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1293-1300.	5.0	373
11	Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. <i>Lancet Oncology</i> , The, 2007, 8, 304-310.	10.7	370
12	Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection. <i>Journal of Clinical Oncology</i> , 2004, 22, 3255-3260.	1.6	339
13	Whole Body ¹⁸ F-FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 428-432.	1.6	338
14	Positron emission tomography for prostate, bladder, and renal cancer. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 274-292.	4.6	312
15	Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. <i>Journal of Clinical Investigation</i> , 2011, 121, 4700-4711.	8.2	305
16	Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. <i>Nature Biotechnology</i> , 2004, 22, 701-706.	17.5	288
17	Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 9578-9582.	7.1	268
18	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. <i>Nature Chemical Biology</i> , 2011, 7, 818-826.	8.0	240

#	ARTICLE	IF	CITATIONS
19	Sequential Cytarabine and β -Particle Immunotherapy with Bismuth-213 α - ¹²⁵ I-Intuzumab (HuM195) for Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 5303-5311.	7.0	234
20	The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , 2016, 538, 397-401.	27.8	233
21	Tumor localization of ¹⁶ beta- ¹⁸ F-fluoro-5alpha-dihydrotestosterone versus ¹⁸ F-FDG in patients with progressive, metastatic prostate cancer. <i>Journal of Nuclear Medicine</i> , 2004, 45, 366-73.	5.0	226
22	Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3525-3530.	1.6	223
23	The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development. <i>Clinical Cancer Research</i> , 2005, 11, 7967-7985.	7.0	219
24	Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 948-948.	1.6	218
25	² -[¹⁸ F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2005, 11, 4761-4769.	7.0	210
26	Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. <i>Urology</i> , 2002, 59, 913-918.	1.0	203
27	Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 187-194.	1.6	201
28	Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1040-1050.	10.7	201
29	Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1775-1782.	7.0	198
30	Patient-specific dosimetry for ¹³¹ I thyroid cancer therapy using ¹²⁴ I PET and 3-dimensional-internal dosimetry (3D-ID) software. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1366-72.	5.0	196
31	The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1287-92.	5.0	189
32	Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. <i>Cancer</i> , 1997, 80, 2505-2509.	4.1	174
33	A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. <i>Clinical Cancer Research</i> , 1998, 4, 1765-72.	7.0	168
34	Vemurafenib Redifferentiation of <i>BRAF</i> Mutant, RAI-Refractory Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1417-1428.	3.6	165
35	A Phase I/II Study for Analytic Validation of ⁸⁹ Zr- ¹²⁵ I ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5277-5285.	7.0	163
36	Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 519-524.	1.6	162

#	ARTICLE	IF	CITATIONS
37	Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³ Ra-dichloride in men with castration-resistant metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1384-1393.	6.4	160
38	Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients. <i>Journal of Clinical Oncology</i> , 2001, 19, 3397-3405.	1.6	159
39	Molecular imaging for personalized cancer care. <i>Molecular Oncology</i> , 2012, 6, 182-195.	4.6	150
40	Targeted alpha particle immunotherapy for myeloid leukemia. <i>Blood</i> , 2002, 100, 1233-9.	1.4	143
41	Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. <i>Nuclear Medicine and Biology</i> , 1996, 23, 693-697.	0.6	140
42	Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. <i>Nature Communications</i> , 2014, 5, 3097.	12.8	139
43	Early tumor response to Hsp90 therapy using HER2 PET: comparison with ¹⁸ F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2006, 47, 793-6.	5.0	136
44	Prognostic Value of Baseline [¹⁸ F] Fluorodeoxyglucose Positron Emission Tomography and ^{99m} Tc-MDP Bone Scan in Progressing Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 6093-6099.	7.0	130
45	⁸⁹ Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2093-2105.	6.4	130
46	Quantitative imaging of iodine-124 with PET. <i>Journal of Nuclear Medicine</i> , 1996, 37, 1557-62.	5.0	130
47	Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: ²¹³ Bi-HuM195 (anti-CD33) in patients with leukemia. <i>Journal of Nuclear Medicine</i> , 1999, 40, 1935-46.	5.0	129
48	Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1587-91.	5.0	127
49	Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.. <i>Journal of Clinical Oncology</i> , 1994, 12, 1561-1571.	1.6	125
50	FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 155-164.	2.1	124
51	Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 3210-3216.	7.0	122
52	Integrated Positron Emission Tomography/Computed Tomography May Render Bone Scintigraphy Unnecessary to Investigate Suspected Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3154-3159.	1.6	121
53	Pilot Trial of Unlabeled and Indium-111 Labeled Anti-Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 7454-7461.	7.0	120
54	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. <i>Journal of Clinical Oncology</i> , 2015, 33, 1356-1363.	1.6	120

#	ARTICLE	IF	CITATIONS
55	Preoperative 18[F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values Predict Survival After Esophageal Adenocarcinoma Resection. <i>Annals of Thoracic Surgery</i> , 2006, 81, 1076-1081.	1.3	118
56	Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. <i>Clinical Cancer Research</i> , 1998, 4, 2729-39.	7.0	118
57	First-in-Human Imaging with ⁸⁹ Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1858-1864.	5.0	116
58	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019, 9, 199-209.	9.4	115
59	N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. <i>Medical and Pediatric Oncology</i> , 2001, 36, 227-230.	1.0	114
60	Pharmacokinetic Assessment of the Uptake of ¹⁶ α- ¹⁸ F-Fluoro-5α-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 183-192.	5.0	113
61	Use of PET to monitor the response of lung cancer to radiation treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 861-866.	6.4	108
62	Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers With Radioiodine-Avid Distant Metastases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E829-E836.	3.6	108
63	Split-Dose Technique for FDG PET/CT-guided Percutaneous Ablation: A Method to Facilitate Lesion Targeting and to Provide Immediate Assessment of Treatment Effectiveness. <i>Radiology</i> , 2013, 268, 288-295.	7.3	107
64	[18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Localizes Residual Thyroid Cancer in Patients with Negative Diagnostic 131I Whole Body Scans and Elevated Serum Thyroglobulin Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2291-2302.	3.6	103
65	Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. <i>Bone Marrow Transplantation</i> , 2003, 32, 549-556.	2.4	102
66	The Effect of Posttherapy ¹³¹ I SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1361-1367.	5.0	102
67	Molecular Imaging of EGFR Kinase Activity in Tumors with ¹²⁴ I-Labeled Small Molecular Tracer and Positron Emission Tomography. <i>Molecular Imaging and Biology</i> , 2006, 8, 262-277.	2.6	98
68	Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹ Zr-Trastuzumab in Patients with Esophagogastric Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 161-166.	5.0	96
69	Biodistribution and Dosimetry of ¹⁸ F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. <i>Journal of Nuclear Medicine</i> , 2018, 59, 147-153.	5.0	96
70	Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 217.	7.1	93
71	Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2436-2442.	1.6	92
72	Bone Metastases in Castration-Resistant Prostate Cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival. <i>Radiology</i> , 2014, 271, 220-229.	7.3	88

#	ARTICLE	IF	CITATIONS
73	Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: ²²³ Ra-Dichloride. Journal of Nuclear Medicine, 2014, 55, 268-274.	5.0	86
74	¹²⁴ I-huA33 Antibody PET of Colorectal Cancer. Journal of Nuclear Medicine, 2011, 52, 1173-1180.	5.0	85
75	Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. Journal of Biological Chemistry, 2015, 290, 30018-30029.	3.4	84
76	Validation and clinical utility of prostate cancer biomarkers. Nature Reviews Clinical Oncology, 2013, 10, 225-234.	27.6	83
77	Chemically Treated Activated Carbon Cloths for Removal of Volatile Organic Carbons from Gas Streams: Evidence for Enhanced Physical Adsorption. Environmental Science & Technology, 1995, 29, 1876-1880.	10.0	81
78	PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. Journal of Nuclear Medicine, 1992, 33, 2020-3.	5.0	79
79	Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using ¹¹¹ In-J591: Lesion Detectability and Dosimetric Projections for ⁹⁰ Y Radioimmunotherapy. Journal of Nuclear Medicine, 2008, 49, 1066-1074.	5.0	76
80	The Results of Selective Use of Radioactive Iodine on Survival and on Recurrence in the Management of Papillary Thyroid Cancer, Based on Memorial Sloan-Kettering Cancer Center Risk Group Stratification. Thyroid, 2013, 23, 683-694.	4.5	75
81	Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors. Clinical Cancer Research, 2007, 13, 2707-2713.	7.0	73
82	A Prospective Pilot Study of ⁸⁹ Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. Journal of Urology, 2014, 191, 1439-1445.	0.4	73
83	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Molecular Systems Biology, 2017, 13, 914.	7.2	73
84	Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging. Molecular Imaging and Biology, 1999, 2, 41-46.	0.3	71
85	Positron emission tomography in thyroid cancer management. Seminars in Roentgenology, 2002, 37, 169-174.	0.6	70
86	¹⁸ F-FDG PET/CT for the Prediction and Detection of Local Recurrence After Radiofrequency Ablation of Malignant Lung Lesions. Journal of Nuclear Medicine, 2010, 51, 1833-1840.	5.0	68
87	Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen. Cancer Discovery, 2012, 2, 320-327.	9.4	68
88	Pilot study of ⁶⁸ Ga-DOTA-F(ab ²) ₂ -trastuzumab in patients with breast cancer. Nuclear Medicine Communications, 2013, 34, 1157-1165.	1.1	68
89	³ -Deoxy- ³ -[¹⁸ F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition. Cancer Research, 2007, 67, 11463-11469.	0.9	66
90	Pairwise comparison of ⁸⁹ Zr- and ¹²⁴ I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 985-994.	6.4	65

#	ARTICLE	IF	CITATIONS
91	Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1697-1702.	5.0	64
92	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. <i>EJNMMI Research</i> , 2015, 5, 28.	2.5	63
93	Repeatability of Quantitative ¹⁸ F-NaF PET: A Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1872-1879.	5.0	62
94	Bone Metastases From Thyroid Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 1440-1447.	2.5	61
95	PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1966-71.	5.0	61
96	Radiopharmacology of a simplified technetium-99m-colloid preparation for photoscanning. <i>Journal of Nuclear Medicine</i> , 1966, 7, 817-26.	5.0	59
97	Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. <i>Journal of Nuclear Medicine</i> , 2007, 48, 143-9.	5.0	59
98	Molecular imaging of prostate cancer. <i>Current Opinion in Urology</i> , 2012, 22, 320-327.	1.8	56
99	18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. <i>Journal of Nuclear Medicine</i> , 2006, 47, 901-3.	5.0	56
100	Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. <i>Cancer</i> , 2012, 118, 5454-5462.	4.1	55
101	Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. <i>Cancer Medicine</i> , 2013, 2, 725-733.	2.8	54
102	Single chain antigen binding protein (sFv CC49). <i>Cancer</i> , 1997, 80, 2458-2468.	4.1	52
103	Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1803-1812.	4.1	52
104	Quantitative Assessment of Early [¹⁸ F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone. <i>Journal of Clinical Oncology</i> , 2017, 35, 2829-2837.	1.6	52
105	An iterative technique to segment PET lesions using a Monte Carlo based mathematical model. <i>Medical Physics</i> , 2009, 36, 4803-4809.	3.0	51
106	Quantitative Imaging of Yttrium-86 with PET The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions. <i>Molecular Imaging and Biology</i> , 2000, 3, 85-90.	0.3	50
107	Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 145-149.	2.1	49
108	Developing imaging strategies for castration resistant prostate cancer. <i>Acta Oncologica</i> , 2011, 50, 39-48.	1.8	48

#	ARTICLE	IF	CITATIONS
109	Radioimmunology. Imaging and therapy. <i>Cancer</i> , 1991, 67, 1253-1260.	4.1	47
110	Differential Metabolism and Pharmacokinetics of $^3\text{-}[1\text{-}^{11}\text{C}]\text{-Methionine}$ and $2\text{-}[^{18}\text{F}]\text{-Fluoro-2-deoxy-}^3\text{-glucose (FDG)}$ in Androgen Independent Prostate Cancer. <i>Molecular Imaging and Biology</i> , 1999, 2, 173-181.	0.3	47
111	$^{124}\text{I-huA33}$ Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1878-1885.	5.0	47
112	Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1727-1732.	5.0	46
113	A phase II study of radioimmunotherapy with intraventricular $^{131}\text{I-}\beta\text{F8}$ for medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26754.	1.5	46
114	Global Trends in Hybrid Imaging. <i>Radiology</i> , 2010, 257, 498-506.	7.3	44
115	Murine and humanized constructs of monoclonal antibody m195 (anti-cd33) for the therapy of acute myelogenous leukemia. <i>Cancer</i> , 1994, 73, 1049-1056.	4.1	43
116	Determination of the elemental distribution in cigarette components and smoke by instrumental neutron activation analysis. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 1997, 217, 77-82.	1.5	43
117	Targeted radioimmunotherapy for leptomeningeal cancer using $^{131}\text{I-}\beta\text{F8}$. <i>Medical and Pediatric Oncology</i> , 2000, 35, 716-718.	1.0	43
118	Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. <i>Nuclear Medicine and Biology</i> , 2008, 35, 343-351.	0.6	42
119	Prospective Study of $^3\text{-}^{18}\text{F-Fluorothymidine}$ PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 728-734.	5.0	41
120	Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. <i>Journal of Nuclear Medicine</i> , 2004, 45, 867-77.	5.0	41
121	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. <i>Cancer Cell</i> , 2019, 36, 559-573.e7.	16.8	40
122	Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. <i>Journal of Nuclear Medicine</i> , 2006, 47, 140-9.	5.0	39
123	Evaluation of Elemental Cadmium as a Marker for Environmental Tobacco Smoke. <i>Environmental Science & Technology</i> , 1995, 29, 2311-2316.	10.0	38
124	Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 177-180.	2.4	38
125	Synthesis and Biological Evaluation of a Fluorine-18 Derivative of Dasatinib. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5853-5857.	6.4	38
126	Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity $^{86}\text{Y-}$ or $^{177}\text{Lu-DOTA-Bn}$ binding scFv C825/GPA33 IgG bispecific immunoconjugates. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 925-937.	6.4	38

#	ARTICLE	IF	CITATIONS
127	Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹ Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1517-1523.	5.0	38
128	Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma. , 1997, 80, 1507-1512.		37
129	Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. <i>EJNMMI Research</i> , 2016, 6, 23.	2.5	37
130	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. <i>Nature Communications</i> , 2018, 9, 1629.	12.8	37
131	Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1S-2S.	5.0	36
132	Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1735-1742.	5.0	36
133	Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1894-1900.	5.0	36
134	Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?. <i>Seminars in Oncology</i> , 2013, 40, 375-392.	2.2	34
135	Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2001, 36, 194-196.	1.0	33
136	Advances in positron emission tomography applications for urologic cancers. <i>Current Opinion in Urology</i> , 2008, 18, 65-70.	1.8	33
137	PET quantification with a histogram derived total activity metric: Superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients. <i>Nuclear Medicine and Biology</i> , 2014, 41, 410-418.	0.6	33
138	Clinical radioimmunodetection, 1978-1988: overview and suggestions for standardization of clinical trials. <i>Cancer Research</i> , 1990, 50, 892s-898s.	0.9	33
139	Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. <i>EJNMMI Research</i> , 2016, 6, 7.	2.5	32
140	Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. <i>Theranostics</i> , 2018, 8, 5106-5125.	10.0	32
141	2-18F-Fluoropropionic Acid as a PET Imaging Agent for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1709-1714.	5.0	31
142	A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1865-1871.	5.0	31
143	Improved tumor imaging and therapy via i.v. IgG α -mediated time-sequential modulation of neonatal Fc receptor. <i>Journal of Clinical Investigation</i> , 2007, 117, 2422-2430.	8.2	31
144	Radiofrequency Ablation of Non-Small-Cell Carcinoma of the Lung Under Real-Time FDG PET CT Guidance. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 182-185.	2.0	30

#	ARTICLE	IF	CITATIONS
145	Biodistribution and Dosimetry of Intraventricularly Administered ¹²⁴ I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1794-1801.	5.0	29
146	Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. <i>Cancer</i> , 2015, 121, 3853-3861.	4.1	27
147	Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (²²⁵ Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 768-768.	1.4	27
148	Positron Emission Tomography/Computerized Tomography Functional Imaging of Esophageal and Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2004, 10, 243-250.	2.0	26
149	Repeatability of SUV measurements in serial PET. <i>Medical Physics</i> , 2011, 38, 2629-2638.	3.0	26
150	Pharmacokinetics and Biodistribution of a [⁸⁹ Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Molecular Pharmaceutics</i> , 2019, 16, 3083-3090.	4.6	26
151	Alpha radioimmunotherapy using ²²⁵ Ac-proteus-DOTA for solid tumors - safety at curative doses. <i>Theranostics</i> , 2020, 10, 11359-11375.	10.0	26
152	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2642-2651.	6.4	26
153	Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: Dosimetry calculations incorporating cross-organ beta doses. <i>Nuclear Medicine and Biology</i> , 1996, 23, 1-8.	0.6	25
154	“Artificial Lymphatic System”: A New Approach to Reduce Interstitial Hypertension and Increase Blood Flow, pH and pO ₂ in Solid Tumors. <i>Annals of Biomedical Engineering</i> , 2000, 28, 543-555.	2.5	25
155	Copper-64 labeled liposomes for imaging bone marrow. <i>Nuclear Medicine and Biology</i> , 2016, 43, 781-787.	0.6	25
156	Long-term Effects of Local Irradiation of the Marrow on Erythron and Red Cell Function. <i>Blood</i> , 1970, 36, 617-622.	1.4	24
157	Repetitively dosed docetaxel and ¹⁵³ samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2013, 119, 3186-3194.	4.1	23
158	Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. <i>Science Translational Medicine</i> , 2016, 8, 367ra167.	12.4	23
159	Relative therapeutic efficacy of (¹²⁵ I)- and (¹³¹ I)-labeled monoclonal antibody A33 in a human colon cancer xenograft. <i>Journal of Nuclear Medicine</i> , 2001, 42, 1251-6.	5.0	23
160	Thyroid Cancer Bone Metastasis. <i>Clinical Nuclear Medicine</i> , 2019, 44, e465-e471.	1.3	22
161	Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 881-891.	7.0	21
162	Copper-64 trastuzumab PET imaging: a reproducibility study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 191-198.	0.7	21

#	ARTICLE	IF	CITATIONS
163	Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. <i>Clinical Cancer Research</i> , 2022, 28, 2030-2037.	7.0	21
164	Reproducibility and Repeatability of Semiquantitative ¹⁸ F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1516-1523.	5.0	20
165	Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. <i>Journal of Nuclear Medicine</i> , 2000, 41, 1905-12.	5.0	20
166	A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 532-541.	7.0	19
167	Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with ¹⁸ F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1050-1056.	5.0	19
168	First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5178-5187.	7.0	18
169	Distribution of the erythron and the RES in the bone marrow organ. <i>Journal of Nuclear Medicine</i> , 1967, 8, 430-6.	5.0	18
170	Improved Tumor Targeting With Radiolabeled, Recombinant, Single-Chain, Antigen-Binding Protein. <i>Journal of the National Cancer Institute</i> , 1990, 82, 1173-1174.	6.3	17
171	The Janus Project: The Remaking of Nuclear Medicine and Radiology. <i>Journal of Nuclear Medicine</i> , 2011, 52, 3S-9S.	5.0	17
172	Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 129-132.	1.0	17
173	Arsenic Trioxide as a Radiation Sensitizer for ¹³¹ I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 231-237.	5.0	17
174	I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. <i>EJNMMI Research</i> , 2018, 8, 20.	2.5	17
175	<i>In vivo</i> immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). <i>Oncotarget</i> , 2017, 8, 65917-65931.	1.8	17
176	New PET tracers for evaluation of solid tumor response to therapy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 53, 158-66.	0.7	17
177	Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor- ¹⁸ F-Axis Imaging. <i>Journal of Nuclear Medicine</i> , 2016, 57, 73S-78S.	5.0	16
178	An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy. <i>Bioconjugate Chemistry</i> , 2020, 31, 501-506.	3.6	16
179	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	2.3	16
180	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α -particle therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 15172-15181.	7.1	16

#	ARTICLE	IF	CITATIONS
181	Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 522-530.	3.9	15
182	Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007, 110, 910-910.	1.4	15
183	Recent Achievements in the Development of Radiolabeled Monoclonal Antibodies for Diagnosis, Therapy and Biologic Characterization of Human Tumors. <i>Acta OncolÃ³gica</i> , 1993, 32, 709-715.	1.8	14
184	Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino)pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. <i>Nuclear Medicine and Biology</i> , 2005, 32, 313-321.	0.6	14
185	How to assess background activity. <i>Nuclear Medicine Communications</i> , 2014, 35, 316-324.	1.1	14
186	Overview of clinical radioimmunodetection of human tumors. <i>Cancer</i> , 1994, 73, 832-835.	4.1	13
187	PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1700-1706.	6.4	13
188	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. <i>Clinical Cancer Research</i> , 2021, 27, 2050-2060.	7.0	13
189	The Role of Iodine-124-Positron Emission Tomography Imaging in the Management of Patients with Thyroid Cancer. <i>PET Clinics</i> , 2007, 2, 313-320.	3.0	12
190	Sequential Therapy with Cytarabine and Bismuth-213 (213Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2004, 104, 1790-1790.	1.4	12
191	Evaluation of Arginine Deiminase Treatment in Melanoma Xenografts Using 18F-FLT PET. <i>Molecular Imaging and Biology</i> , 2013, 15, 768-775.	2.6	11
192	¹²⁴ I-Iodopyridopyrimidinone for PET of Abl Kinase-Expressing Tumors In Vivo. <i>Journal of Nuclear Medicine</i> , 2010, 51, 121-129.	5.0	9
193	Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	9
194	Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution. <i>Nuclear Medicine and Biology</i> , 2015, 42, 375-380.	0.6	9
195	IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamabâ€™ pharmacokinetic modeling to optimize therapeutic index. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1166-1177.	6.4	9
196	Evaluation of Glycodendron and Synthetically Modified Dextran Clearing Agents for Multistep Targeting of Radioisotopes for Molecular Imaging and Radioimmunotherapy. <i>Molecular Pharmaceutics</i> , 2014, 11, 400-416.	4.6	8
197	Imaging Sigma-1 Receptor (S1R) Expression Using Iodine-124-Labeled 1-(4-Iodophenyl)-3-(2-adamantyl)guanidine ([124I]IPAG). <i>Molecular Imaging and Biology</i> , 2020, 22, 358-366.	2.6	8
198	Single chain antigen binding protein (sFv CC49). <i>Cancer</i> , 1997, 80, 2458-2468.	4.1	8

#	ARTICLE	IF	CITATIONS
199	Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, 31-31.	1.6	8
200	Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer. Molecular Imaging and Radionuclide Therapy, 2017, 26, 80-86.	0.7	8
201	¹³¹ I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft. Journal of Nuclear Medicine, 1999, 40, 1764-8.	5.0	8
202	Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience. Current Pharmaceutical Design, 2009, 15, 950-956.	1.9	7
203	EXINI Quantitative Bone Scan Index: Expanded Utility for the Planar Radionuclide Bone Scan. Journal of Nuclear Medicine, 2016, 57, 5-6.	5.0	7
204	Repeatability of [⁶⁸ Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. Molecular Imaging and Biology, 2017, 19, 944-951.	2.6	7
205	CAR Chase: Where Do Engineered Cells Go in Humans?. Frontiers in Oncology, 2020, 10, 577773.	2.8	7
206	Enhancing the Uptake of Chemotherapeutic Drugs into Tumors using an "Artificial Lymphatic System". Annals of Biomedical Engineering, 2000, 28, 556-564.	2.5	6
207	³ H-Tocotrienol-Loaded Liposomes for Radioprotection from Hematopoietic Side Effects Caused by Radiotherapeutic Drugs. Journal of Nuclear Medicine, 2021, 62, 584-590.	5.0	6
208	Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjugate Chemistry, 2021, 32, 649-654.	3.6	6
209	<i>N</i> -Acetylgalactosamino Dendrons as Clearing Agents to Enhance Liver Targeting of Model Antibody-Fusion Protein. Bioconjugate Chemistry, 2013, 24, 2088-2103.	3.6	5
210	First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. Journal of Nuclear Medicine, 2020, 61, 1580-1587.	5.0	5
211	Using ¹²⁴ I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71.. Journal of Clinical Oncology, 2013, 31, 11076-11076.	1.6	5
212	Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. Molecular Cancer Therapeutics, 2022, 21, 125-137.	4.1	5
213	Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8. Journal of Neuro-Oncology, 1993, 15, 235-242.	2.9	4
214	ImmunopET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts. Molecular Pharmaceutics, 2018, 15, 2133-2141.	4.6	4
215	A pragmatic perspective on molecular targeted radionuclide therapy. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 1S-3S.	5.0	4
216	Chemical Consequences Resulting from Multi-millicurie Preparation of 6- ¹⁸ F-Fluoro-6-deoxy-L-ascorbic Acid. Radiochimica Acta, 1997, 77, 87-89.	1.2	3

#	ARTICLE	IF	CITATIONS
217	Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?. <i>Annals of Oncology</i> , 2013, 24, 1948-1949.	1.2	3
218	Better use of bone scans in prostate cancer. <i>Nature Reviews Urology</i> , 2015, 12, 190-191.	3.8	3
219	TMSOTf assisted synthesis of 2â€™-deoxy-2â€™-[18F]fluoro-âˆ†-D-arabinofuranosylcytosine ([18F]FAC). <i>PLoS ONE</i> , 2018, 13, e0196784.	2.5	3
220	Acid-Sphingomyelinase Triggered Fluorescently Labeled Sphingomyelin Containing Liposomes in Tumor Diagnosis after Radiation-Induced Stress. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3864.	4.1	3
221	Tumor biology as a basis for molecular targeting in cancer. <i>Clinical and Translational Imaging</i> , 2013, 1, 397-406.	2.1	2
222	Gallagherâ€™s Principle of Metabolic Trapping (perspective on â€œMetabolic Trapping as a Principle of Tumor Imagingâ€). <i>Journal of Nuclear Medicine</i> , 2020, 61, 74S-82S.	5.0	2
223	Long-term effects of local irradiation of the marrow on erythron and red cell function. <i>Blood</i> , 1970, 36, 617-22.	1.4	2
224	Advances in imaging. <i>Seminars in Oncology</i> , 1994, 21, 598-606.	2.2	2
225	Optimizing reconstruction parameters for quantitative 124I-PET in the presence of therapeutic doses of 131I. <i>EJNMMI Physics</i> , 2021, 8, 50.	2.7	1
226	N7: A novel multimodality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. <i>Medical and Pediatric Oncology</i> , 2001, 36, 227-230.	1.0	1
227	Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, , .	1.9	1
228	Cancer Biology of Molecular Imaging. , 2017, , 3-34.		0
229	Molecular Imaging, Clinical Trial Design, and the Development of Emerging Therapies for Metastatic Prostate Cancer. <i>Translational Medicine Series</i> , 2006, , 291-313.	0.0	0
230	The Future of Molecular Imaging. , 2008, , 693-704.		0
231	Cancer Biology of Molecular Imaging. , 2016, , 1-31.		0
232	Loss of a pioneer: Hussein Abdel-Dayem, MD 1934-2017. <i>World Journal of Nuclear Medicine</i> , 2017, 16, 255.	0.5	0